Effects of sodium-glucose co-transporter-2 inhibitors on body composition and liver fat markers in non-alcoholic fatty liver disease: a narrative review.

Chehrehgosha et al [ 20 ] reported a marked within-group CAP reduction with empagliflozin (317.37 ± 28.46 to 287.80 ± 31.14 dB/m), though the between-group difference versus placebo was borderline significant (−29.6 vs. −16.4 dB/m, P = 0.05).

also in 11,409 other papers